RECORD // Company

KALA BIO, Inc.

Formerly: KALA BIO, Inc.; Kala Pharmaceuticals, Inc.

Built 2026-11-21T07:36:19Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (3)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • KALA BIO, INC. · Ct business · same registered legal name as 'KALA BIO, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KALA BIO, INC. · Ct business · same registered legal name as 'KALA BIO, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KALA BIO, INC. · Ct business · same registered legal name as 'KALA BIO, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KALA PHARMACEUTICALS · Epa echo · name equals 'Kala Pharmaceuticals' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-19 · accession 0001104659-26-098783

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-1,581,0003 months ended 2026-06-3010-Q2026-08-190001104659-26-0987832026-11-21 07:36 UTCReport an error
Cash and cash equivalents$229,000at 2026-06-3010-Q2026-08-190001104659-26-0987832026-11-21 07:36 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001479419
Ticker
KALA
EIN
270604595
CUSIP
483119301
Record ID
sx:sec:0001479419

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

36 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
Business address1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 024762026-11-16SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 07:36 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax2026-11-21 07:36 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-26,980,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 07:36 UTCReport an error
Total assets (at 2025-12-31)$9,490,0002025-12-3110-K, XBRL Assets2026-11-21 07:36 UTCReport an error
Stockholders' equity (at 2025-12-31)$6,996,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 07:36 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$7,557,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 07:36 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-31,991,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 07:36 UTCReport an error
Long-term debt (at 2024-12-31)$29,284,0002024-12-3110-K, XBRL LongTermDebt2026-11-21 07:36 UTCReport an error
Operating lease liabilities (at 2024-12-31)$1,814,0002024-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 07:36 UTCReport an error
Form D total offering amount (D filed 2026-03-17)$1,753,5002026-03-17D2026-11-21 07:36 UTCReport an error
Form D total amount sold (D filed 2026-03-17)$1,753,5002026-03-17D2026-11-21 07:36 UTCReport an error
Form D industry groupPharmaceuticals2026-03-17D2026-11-21 07:36 UTCReport an error
Form D revenue rangeDecline to Disclose2026-03-17D2026-11-21 07:36 UTCReport an error
Form D date of first sale2026-03-032026-03-17D2026-11-21 07:36 UTCReport an error
8-K Item 8.01, Other Items (filed 2026-11-16)On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from July 16, 2026 through August 26, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2). On October 6, 2026, the…2026-11-16SEC EDGAR 8-K 0001829126-26-012439 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 3.03, Material Modification to Rights of Security Holders (filed 2026-11-12)To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.2026-11-12SEC EDGAR 8-K 0001829126-26-012313 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change (filed 2026-11-12)in Fiscal Year. On November 12, 2026, KALA BIO, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-30 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on November 13, 2026 (the “Reverse Stock Split”). As previously reported, the Company held its 2026 annual meeting of stockholders on November 3, 2026 (the “Annual…2026-11-12SEC EDGAR 8-K 0001829126-26-012313 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-12)On November 12, 2026, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. 12026-11-12SEC EDGAR 8-K 0001829126-26-012313 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, KALA BIO Inc. issued a press release announcing its certain preliminary financial results for the quarter ended September 30, 2026. The press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof…2026-11-09SEC EDGAR 8-K 0001829126-26-012118 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
8-K Item 5.07, Submission (filed 2026-11-03)of Matters to a Vote of Security Holders. A total of 14,459,767 shares of the Company’s Common Stock were present in person or represented by proxy at the Annual Meeting. At the Annual Meeting, stockholders voted in favor of the following items of business: Proposal No. 1 – Election of Directors The Company’s stockholders voted to elect the following persons to the board of directors of the Company as Class III directors to serve until the 2029 Annual Meeting of Stockholders, and until their successors have been duly elected and qualified or until their earlier death, resignation or removal. Nominee Votes For Votes Withheld Broker Non-Votes Yonatan Colman 13,485,088 138,862 835,817 Brendan…2026-11-03SEC EDGAR 8-K 0001829126-26-011934 (text as filed, excerpt)2026-11-21 07:36 UTCReport an error
Plan (pension, plan no. 001)KALA BIO 401(K) PLAN: 80 participants, assets $8,517,5052025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 07:36 UTCReport an error
Largest institutional holder #1 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$381,6782026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #2 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$251,1122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD FIDUCIARY TRUST CO$175,4152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #4 (13F as filed): BlackRock, Inc.$123,7682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #5 (13F as filed): NORTHERN TRUST CORP$71,9782026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #6 (13F as filed): Qube Research & Technologies Ltd$19,1562026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #7 (13F as filed): GOLDMAN SACHS GROUP INC$18,8932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #8 (13F as filed): UBS Group AG$15,6692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #9 (13F as filed): Tower Research Capital LLC (TRC)$1,0662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error
Largest institutional holder #10 (13F as filed): BARCLAYS PLC$1,0522026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:36 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.